Interferon alpha-2b/interferon gamma - Heber Biotech

Alternative Names: CIGB-128; CIGB-128-A; HeberFERON; HeberPAG; Interferon-alpha-2b/interferon-gamma; Interferon-gamma/interferon-alpha-2b

Latest Information Update: 28 Feb 2018

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Center for Genetic Engineering and Biotechnology
Class Antineoplastics; Antivirals; Interferons; Lymphokines
Mechanism of Action Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Phase II Basal cell cancer
No development reported Brain cancer; Mycosis fungoides

Most Recent Events

28 Feb 2018 No recent reports of development identified for phase-I development in Mycosis-fungoides in Cuba (IM)
28 Feb 2018 No recent reports of development identified for preclinical development in Brain-cancer in Cuba (IV)
09 Jan 2017 Center for Genetic Engineering and Biotechnology plans a phase I/II trial in Renal cell carcinoma in Cuba (RPCEC00000229)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.